PL2888269T3 - Hapteny olanzapiny - Google Patents

Hapteny olanzapiny

Info

Publication number
PL2888269T3
PL2888269T3 PL13753774T PL13753774T PL2888269T3 PL 2888269 T3 PL2888269 T3 PL 2888269T3 PL 13753774 T PL13753774 T PL 13753774T PL 13753774 T PL13753774 T PL 13753774T PL 2888269 T3 PL2888269 T3 PL 2888269T3
Authority
PL
Poland
Prior art keywords
olanzapine
haptens
Prior art date
Application number
PL13753774T
Other languages
English (en)
Inventor
Matthew Garrett DONAHUE
Yong Gong
Rhys Salter
Eric Hryhorenko
Thomas R. DECORY
Bart M. REMMERIE
Banumathi Sankaran
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL2888269T3 publication Critical patent/PL2888269T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/77Ovalbumin
PL13753774T 2012-08-21 2013-08-20 Hapteny olanzapiny PL2888269T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691454P 2012-08-21 2012-08-21
PCT/US2013/055700 WO2014031587A1 (en) 2012-08-21 2013-08-20 Haptens of olanzipine
EP13753774.2A EP2888269B1 (en) 2012-08-21 2013-08-20 Haptens of olanzapine

Publications (1)

Publication Number Publication Date
PL2888269T3 true PL2888269T3 (pl) 2019-06-28

Family

ID=49081007

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13753774T PL2888269T3 (pl) 2012-08-21 2013-08-20 Hapteny olanzapiny

Country Status (12)

Country Link
US (1) US9303041B2 (pl)
EP (2) EP3492473A1 (pl)
JP (3) JP6171014B2 (pl)
CN (1) CN104854110B (pl)
AU (1) AU2013306018B2 (pl)
CA (1) CA2882454C (pl)
ES (1) ES2701062T3 (pl)
HK (1) HK1211933A1 (pl)
PL (1) PL2888269T3 (pl)
PT (1) PT2888269T (pl)
TR (1) TR201816378T4 (pl)
WO (1) WO2014031587A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2888234B1 (en) 2012-08-21 2017-12-06 Janssen Pharmaceutica NV Haptens of aripiprazole and their use in immunoassays
EP3333195B1 (en) 2012-08-21 2020-08-05 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
PL2888269T3 (pl) * 2012-08-21 2019-06-28 Janssen Pharmaceutica Nv Hapteny olanzapiny
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ.ベー. アリピプラゾールハプテンに対する抗体及びその使用
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
AU2013305965B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
AU2013305901B2 (en) 2012-08-21 2017-10-26 Saladax Biomedical Inc. Antibodies to olanzapine and use thereof
US9664700B2 (en) 2012-08-21 2017-05-30 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
PT3663317T (pt) 2012-08-21 2023-01-23 Janssen Pharmaceutica Nv Anticorpos para haptenos de quetiapina e sua utilização
EP2888287A4 (en) 2012-08-21 2016-04-20 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
EP3390449A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica N.V. Antibodies to risperidone and use thereof
AU2016370853A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
CN110950808A (zh) * 2019-10-30 2020-04-03 杭州博拓生物科技股份有限公司 一种氯氮平人工抗原及其制备方法
CN110938082A (zh) * 2019-10-30 2020-03-31 杭州博拓生物科技股份有限公司 一种奥氮平人工抗原及其制备方法
CN114685527B (zh) * 2020-12-25 2024-03-05 长沙博源医疗科技有限公司 一种奥氮平衍生物、免疫原、抗奥氮平特异性抗体及其制备方法与应用
CN114685477B (zh) * 2020-12-25 2023-11-17 长沙博源医疗科技有限公司 一种利奈唑胺衍生物、免疫原、抗利奈唑胺特异性抗体及其制备方法与应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022780A (en) 1973-03-06 1977-05-10 Imperial Chemical Industries Limited Process for the manufacture of indole derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
ES2153373T3 (es) 1992-05-29 2001-03-01 Lilly Co Eli Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central.
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
ATE176329T1 (de) * 1992-06-26 1999-02-15 Johnson & Johnson Clin Diag Immunotests unter verwendung von markierten thyronin-analogen
US5395933A (en) * 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
UA76708C2 (uk) * 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
ATE380818T1 (de) * 2002-03-28 2007-12-15 Lilly Co Eli Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
PT1546134E (pt) * 2002-08-05 2007-08-10 Lilly Co Eli ''arilbenzodiazepinas substituídas com piperazina''
US7863441B2 (en) * 2003-09-23 2011-01-04 Fermion Oy Preparation of quetiapine
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
CA2577490A1 (en) * 2004-08-26 2006-03-16 Nicholas Piramal India Limited Prodrugs containing alkyldisulfide linker groups
JP2010540920A (ja) * 2007-09-27 2010-12-24 ノバルティス アーゲー 薬物モニタリングアッセイ
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
AU2009305203B2 (en) 2008-10-14 2013-03-07 Entasis Therapeutics Limited Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
JP5544024B2 (ja) 2009-12-31 2014-07-09 ケムファーム・インコーポレーテッド クエチアピンのアミノ酸結合体、その製造法及び使用法
PL2544536T3 (pl) 2010-03-11 2019-05-31 Kempharm Inc Koniugaty kwasów tłuszczowych z kwetiapiną, sposób ich wytwarzania i stosowania
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
JP5757497B2 (ja) * 2010-10-06 2015-07-29 公立大学法人大阪府立大学 シガトキシン類ctx1bおよび54−デオキシ−ctx1bを認識するモノクローナル抗体およびそれを用いるシガトキシン類検出キット
US8969337B2 (en) * 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
PL2888269T3 (pl) * 2012-08-21 2019-06-28 Janssen Pharmaceutica Nv Hapteny olanzapiny

Also Published As

Publication number Publication date
PT2888269T (pt) 2019-01-17
WO2014031587A1 (en) 2014-02-27
JP6763000B2 (ja) 2020-09-30
AU2013306018A1 (en) 2015-03-12
TR201816378T4 (tr) 2018-11-21
JP6171014B2 (ja) 2017-07-26
CA2882454A1 (en) 2014-02-27
JP2017222671A (ja) 2017-12-21
CN104854110A (zh) 2015-08-19
HK1211933A1 (en) 2016-06-03
EP2888269B1 (en) 2018-10-24
JP6423490B2 (ja) 2018-11-14
ES2701062T3 (es) 2019-02-20
CN104854110B (zh) 2016-12-28
CA2882454C (en) 2020-08-11
US20140213766A1 (en) 2014-07-31
JP2019034955A (ja) 2019-03-07
EP3492473A1 (en) 2019-06-05
AU2013306018B2 (en) 2017-08-10
JP2015532645A (ja) 2015-11-12
US9303041B2 (en) 2016-04-05
EP2888269A1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
PT2888269T (pt) Haptenos de olanzapina
HK1214259A1 (zh) 衍生物
HK1211934A1 (en) Haptens of paliperidone
HK1206723A1 (en) Thienopyrimidines
HK1211857A1 (en) Antibodies to olanzapine haptens and use thereof
EP2861655A4 (en) METHODS OF DEOLVANTIZATION OF BAGASSE
ZA201406082B (en) Use of ccr3-inhibitors
HK1203949A1 (en) Inhibitors of iap iap
GB201222832D0 (en) Manufacture of hollow parts
IL236312A0 (en) Preparation of 18f-flucyclobin
HUE041814T2 (hu) Eljárás izoidid elõállítására
GB201509165D0 (en) Tampon method of manufacture
EP2866757A4 (en) BUFFER MANUFACTURING METHOD
GB201220155D0 (en) Method of manufacture
IL237862A0 (en) Methods to reduce the formation of scale
HK1214601A1 (zh) 用於製造 -標記物的新型雙-銥-配合物
EP2892529A4 (en) USES OF (-) - PERHEXILINE
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
GB2508089B (en) Underpants
GB201215033D0 (en) Diazepinone derivatives
GB201215942D0 (en) Method of treatent
ZA201503833B (en) Method of hemoglobin-f determination
GB201205098D0 (en) Method of calibration
LT2928896T (lt) Dihidro-pirido-oksazino darinio kieta forma
TWM433525U (en) Structure of calorifier